Study summary · research use only
Ifosfamide encephalopathy
Plain-language summary
Paraphrased from the published abstract below — not a verdict on whether anything works.
This review discusses ifosfamide encephalopathy in humans as a potentially fatal toxicity of the chemotherapy agent ifosfamide. The authors describe clinical manifestations ranging from fatigue and confusion to coma and death, and state that early identification and prompt cessation of ifosfamide are essential to management. They note that accurate prediction of this toxicity is often difficult and that, based on limited available evidence, methylene blue, an electron acceptor, may have a role in treatment and prevention of the neurotoxicity. The paper reviews the current understanding of the condition rather than presenting new experimental data.
Abstract
Encephalopathy is a potentially fatal toxicity of ifosfamide. Clinical manifestations of encephalopathy range from fatigue and confusion to coma and death. Early identification of this toxicity and prompt cessation of ifosfamide are the essential elements in the management of ifosfamide encephalopathy. Accurate prediction of this toxicity is often difficult. Based on the limited available evidence, methylene blue, an electron acceptor, may have a role in the treatment and the prevention of neurotoxicity. This paper reviews the current understanding of ifosfamide encephalopathy.
pepmg summarizes the peer-reviewed literature and links to every source — it sells nothing, ships nothing, and gives no medical, dosing, or human-use guidance. Don't just trust this summary: follow the citation to its source and read it yourself. Research use only.